Flagship Harbor Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.89M | Buy |
4,913
+211
| +4% | +$216K | 0.23% | 106 |
|
|
2026
Q1 | $4.32M | Sell |
4,702
-80
| -2% | -$81.1K | 0.19% | 122 |
|
|
2025
Q4 | $5.14M | Sell |
4,782
-1,552
| -25% | -$1.48M | 0.24% | 100 |
|
|
2025
Q3 | $4.83M | Buy |
6,334
+108
| +2% | +$80.4K | 0.21% | 110 |
|
|
2025
Q2 | $4.85M | Buy |
6,226
+37
| +0.6% | +$28.8K | 0.23% | 104 |
|
|
2025
Q1 | $5.11M | Sell |
6,189
-353
| -5% | -$294K | 0.27% | 81 |
|
|
2024
Q4 | $5.05M | Sell |
6,542
-370
| -5% | -$306K | 0.27% | 76 |
|
|
2024
Q3 | $6.12M | Sell |
6,912
-29
| -0.4% | -$26.1K | 0.34% | 64 |
|
|
2024
Q2 | $6.28M | Buy |
6,941
+474
| +7% | +$379K | 0.38% | 58 |
|
|
2024
Q1 | $5.03M | Buy |
6,467
+599
| +10% | +$426K | 0.32% | 66 |
|
|
2023
Q4 | $3.42M | Buy |
5,868
+605
| +11% | +$353K | 0.25% | 92 |
|
|
2023
Q3 | $2.83M | Sell |
5,263
-13
| -0.2% | -$6.7K | 0.24% | 99 |
|
|
2023
Q2 | $2.47M | Buy |
5,276
+773
| +17% | +$324K | 0.2% | 111 |
|
|
2023
Q1 | $1.55M | Buy |
4,503
+804
| +22% | +$271K | 0.15% | 162 |
|
|
2022
Q4 | $1.35M | Sell |
3,699
-89
| -2% | -$31.6K | 0.14% | 173 |
|
|
2022
Q3 | $1.23M | Sell |
3,788
-279
| -7% | -$88.4K | 0.14% | 170 |
|
|
2022
Q2 | $1.32M | Sell |
4,067
-219
| -5% | -$65.7K | 0.15% | 168 |
|
|
2022
Q1 | $1.23M | Buy |
4,286
+218
| +5% | +$56.1K | 0.12% | 197 |
|
|
2021
Q4 | $1.12M | Buy |
4,068
+304
| +8% | +$77.1K | 0.11% | 208 |
|
|
2021
Q3 | $864K | Hold |
3,764
| – | – | 0.09% | 235 |
|
|
2021
Q2 | $864K | Buy |
3,764
+103
| +3% | +$20.7K | 0.09% | 236 |
|
|
2021
Q1 | $684K | Buy |
3,661
+416
| +13% | +$81.4K | 0.08% | 273 |
|
|
2020
Q4 | $548K | Buy |
3,245
+229
| +8% | +$34.2K | 0.07% | 285 |
|
|
2020
Q3 | $446K | Buy |
3,016
+215
| +8% | +$33.3K | 0.06% | 277 |
|
|
2020
Q2 | $459K | Buy |
2,801
+226
| +9% | +$34.7K | 0.07% | 269 |
|
|
2020
Q1 | $357K | Sell |
2,575
-863
| -25% | -$119K | 0.07% | 262 |
|
|
2019
Q4 | $452K | Sell |
3,438
-112
| -3% | -$13K | 0.08% | 250 |
|
|
2019
Q3 | $397K | Sell |
3,550
-243
| -6% | -$27.1K | 0.08% | 257 |
|
|
2019
Q2 | $420K | Buy |
3,793
+660
| +21% | +$77.7K | 0.09% | 237 |
|
|
2019
Q1 | $406K | Buy |
3,133
+1,109
| +55% | +$135K | 0.08% | 250 |
|
|
2018
Q4 | $234K | Sell |
2,024
-135
| -6% | -$15.1K | 0.06% | 314 |
|
|
2018
Q3 | $232K | Buy |
2,159
+4
| +0.2% | +$400 | 0.04% | 376 |
|
|
2018
Q2 | $183K | Buy |
+2,155
| New | +$177K | 0.04% | 420 |
|
Other funds holding LLY
SC
ONB
GIM
Flagship Harbor Advisors's LLY Position: Q2 2026 in Review
Flagship Harbor Advisors increased its Eli Lilly (LLY) stake by 4.5% in Q2 2026, buying an estimated $216K and bringing the position to 4,913 shares worth $5.89M. The position accounts for 0.23% of the portfolio, ranked #106.
Flagship Harbor Advisors first reported a position in LLY in Q2 2018 and has held it in 33 quarters since. The position peaked at $6.28M in Q2 2024. 1,713 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Flagship Harbor Advisors held 4,913 shares of Eli Lilly worth $5.89M as of Q2 2026.
- Flagship Harbor Advisors bought 211 Eli Lilly shares in Q2 2026, an estimated $216K.
- Eli Lilly made up 0.23% of Flagship Harbor Advisors's portfolio in Q2 2026, its #106 holding.
- Flagship Harbor Advisors first reported a position in Eli Lilly in Q2 2018 and has held it in 33 quarters since.
- Flagship Harbor Advisors's Eli Lilly position peaked at $6.28M in Q2 2024.
- 1,713 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.